

# Adrian V S Hill

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7612716/publications.pdf>

Version: 2024-02-01

275  
papers

38,420  
citations

3525

90  
h-index

3402

183  
g-index

288  
all docs

288  
docs citations

288  
times ranked

40168  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	6.3	3,887
2	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478.	6.3	2,080
3	Common West African HLA antigens are associated with protection from severe malaria. <i>Nature</i> , 1991, 352, 595-600.	13.7	1,494
4	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	6.3	1,196
5	Variation in the TNF- $\alpha$ promoter region associated with susceptibility to cerebral malaria. <i>Nature</i> , 1994, 371, 508-511.	13.7	1,169
6	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979
7	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	15.2	900
8	Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. <i>Nature Medicine</i> , 1998, 4, 397-402.	15.2	640
9	Molecular analysis of the association of HLA-B53 and resistance to severe malaria. <i>Nature</i> , 1992, 360, 434-439.	13.7	638
10	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	6.3	540
11	Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. <i>Nature Medicine</i> , 2004, 10, 1240-1244.	15.2	538
12	Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. <i>Nature Medicine</i> , 2003, 9, 729-735.	15.2	536
13	Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2016, 4, 259-271.	5.2	536
14	In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. <i>Nature Medicine</i> , 2000, 6, 337-342.	15.2	521
15	THE IMMUNOGENETICS OF HUMAN INFECTIOUS DISEASES. <i>Annual Review of Immunology</i> , 1998, 16, 593-617.	9.5	513
16	Efficacy of RTS,S/AS02 malaria vaccine against <i>Plasmodium falciparum</i> infection in semi-immune adult men in The Gambia: a randomised trial. <i>Lancet, The</i> , 2001, 358, 1927-1934.	6.3	485
17	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	15.2	473
18	Bayesian refinement of association signals for 14 loci in 3 common diseases. <i>Nature Genetics</i> , 2012, 44, 1294-1301.	9.4	469

#	ARTICLE	IF	CITATIONS
19	Genetics of susceptibility to human infectious disease. <i>Nature Reviews Genetics</i> , 2001, 2, 967-977.	7.7	447
20	Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1. <i>Clinical Infectious Diseases</i> , 2011, 52, 1-7.	2.9	424
21	Human genetic susceptibility to infectious disease. <i>Nature Reviews Genetics</i> , 2012, 13, 175-188.	7.7	413
22	Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man. <i>Science Translational Medicine</i> , 2012, 4, 115ra1.	5.8	356
23	Vaccines against intracellular infections requiring cellular immunity. <i>Nature</i> , 2000, 406, 793-798.	13.7	334
24	Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2. <i>Nature Genetics</i> , 2010, 42, 739-741.	9.4	332
25	Identifying Recent Adaptations in Large-Scale Genomic Data. <i>Cell</i> , 2013, 152, 703-713.	13.5	325
26	Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. <i>Nature Genetics</i> , 2015, 47, 717-726.	9.4	310
27	A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity. <i>PLoS ONE</i> , 2012, 7, e40385.	1.1	301
28	A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. <i>Science Translational Medicine</i> , 2014, 6, 261ra153.	5.8	297
29	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. <i>New England Journal of Medicine</i> , 2016, 374, 1635-1646.	13.9	295
30	Heterozygote advantage for HLA class-II type in hepatitis B virus infection. <i>Nature Genetics</i> , 1997, 17, 11-12.	9.4	291
31	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	15.2	265
32	Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species. <i>Science Translational Medicine</i> , 2012, 4, 115ra2.	5.8	257
33	Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. <i>Nature Communications</i> , 2013, 4, 2836.	5.8	256
34	Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. <i>Lancet</i> , The, 2021, 397, 1809-1818.	6.3	253
35	Aspects of Genetic Susceptibility to Human Infectious Diseases. <i>Annual Review of Genetics</i> , 2006, 40, 469-486.	3.2	244
36	The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. <i>Nature Communications</i> , 2011, 2, 601.	5.8	233

#	ARTICLE	IF	CITATIONS
37	Severe Malarial Anemia and Cerebral Malaria Are Associated with Different Tumor Necrosis Factor Promoter Alleles. <i>Journal of Infectious Diseases</i> , 1999, 179, 287-290.	1.9	231
38	Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 4836-4841.	3.3	228
39	THE GENOMICS AND GENETICS OF HUMAN INFECTIOUS DISEASES SUSCEPTIBILITY. <i>Annual Review of Genomics and Human Genetics</i> , 2001, 2, 373-400.	2.5	227
40	Preliminary Assessment of the Efficacy of a T-Cell-Based Influenza Vaccine, MVA-NP+M1, in Humans. <i>Clinical Infectious Diseases</i> , 2012, 55, 19-25.	2.9	224
41	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet</i> , The, 2021, 398, 981-990.	6.3	214
42	Enhanced Immunogenicity of CD4+ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis. <i>Infection and Immunity</i> , 2001, 69, 681-686.	1.0	213
43	Glucose-6-phosphate dehydrogenase deficiency and malaria. <i>Journal of Molecular Medicine</i> , 1998, 76, 581-588.	1.7	210
44	ChAd63-MVA-vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. <i>Molecular Therapy</i> , 2012, 20, 2355-2368.	3.7	196
45	Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. <i>Journal of Infectious Diseases</i> , 2012, 205, 772-781.	1.9	194
46	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV</i> , The, 2021, 8, e474-e485.	2.1	190
47	Viral vectors as vaccine platforms: deployment in sight. <i>Current Opinion in Immunology</i> , 2011, 23, 377-382.	2.4	188
48	Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1. <i>Molecular Therapy</i> , 2014, 22, 464-475.	3.7	188
49	Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 31-42.	4.6	187
50	Prime-boost vectored malaria vaccines: Progress and prospects. <i>Hum Vaccin</i> , 2010, 6, 78-83.	2.4	184
51	Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 816-826.	4.6	182
52	Induction of CD8+ T cells using heterologous prime-boost immunisation strategies. <i>Immunological Reviews</i> , 1999, 170, 29-38.	2.8	179
53	Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8 T-Cell Responses. <i>Infection and Immunity</i> , 2010, 78, 145-153.	1.0	178
54	Shared and Distinct Aspects of the Sepsis Transcriptomic Response to Fecal Peritonitis and Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 328-339.	2.5	178

#	ARTICLE	IF	CITATIONS
55	A major susceptibility locus for leprosy in India maps to chromosome 10p13. <i>Nature Genetics</i> , 2001, 27, 439-441.	9.4	171
56	Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. <i>Lancet Respiratory Medicine</i> , 2015, 3, 53-60.	5.2	166
57	Vaccines against malaria. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2011, 366, 2806-2814.	1.8	165
58	Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vected Vaccine Expressing Conserved Influenza A Antigens. <i>Molecular Therapy</i> , 2014, 22, 668-674.	3.7	165
59	Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. <i>Scientific Reports</i> , 2017, 7, 46621.	1.6	158
60	Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors. <i>PLoS ONE</i> , 2012, 7, e31208.	1.1	157
61	Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. <i>Vaccine</i> , 2002, 20, 1039-1045.	1.7	156
62	Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors. <i>Molecular Therapy</i> , 2011, 19, 2269-2276.	3.7	156
63	Heterogeneity of Microsatellite Mutations Within and Between Loci, and Implications for Human Demographic Histories. <i>Genetics</i> , 1998, 148, 1269-1284.	1.2	154
64	A protein particle vaccine containing multiple malaria epitopes. <i>Nature Biotechnology</i> , 1997, 15, 1280-1284.	9.4	153
65	Calculation of Liver Blood Inocula, Parasite Growth Rates, and Preerythrocytic Vaccine Efficacy, from Serial Quantitative Polymerase Chain Reaction Studies of Volunteers Challenged with Malaria Sporozoites. <i>Journal of Infectious Diseases</i> , 2005, 191, 619-626.	1.9	152
66	Potent Induction of Focused Th1 Type Cellular and Humoral Immune Responses by RTS,S/SBAS2, a Recombinant Plasmodium falciparum Malaria Vaccine. <i>Journal of Infectious Diseases</i> , 1999, 180, 1656-1664.	1.9	148
67	Effective induction of high-titer antibodies by viral vector vaccines. <i>Nature Medicine</i> , 2008, 14, 819-821.	15.2	148
68	Differential Immunogenicity of Various Heterologous Prime-Boost Vaccine Regimens Using DNA and Viral Vectors in Healthy Volunteers. <i>Journal of Immunology</i> , 2005, 174, 449-455.	0.4	143
69	Coated microneedle arrays for transcutaneous delivery of live virus vaccines. <i>Journal of Controlled Release</i> , 2012, 159, 34-42.	4.8	141
70	Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass. <i>Science Translational Medicine</i> , 2010, 2, 19ra12.	5.8	139
71	Innate Immune Responses to Human Malaria: Heterogeneous Cytokine Responses to Blood-Stage Plasmodium falciparum Correlate with Parasitological and Clinical Outcomes. <i>Journal of Immunology</i> , 2006, 177, 5736-5745.	0.4	138
72	Viral vectors as vaccine platforms: from immunogenicity to impact. <i>Current Opinion in Immunology</i> , 2016, 41, 47-54.	2.4	137

#	ARTICLE	IF	CITATIONS
73	ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. <i>Vaccine</i> , 2017, 35, 3780-3788.	1.7	133
74	Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness. <i>Hepatology</i> , 2005, 41, 1383-1390.	3.6	125
75	Pre-erythrocytic malaria vaccines: towards greater efficacy. <i>Nature Reviews Immunology</i> , 2006, 6, 21-32.	10.6	125
76	A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. <i>PLOS Clinical Trials</i> , 2006, 1, e29.	3.5	124
77	Durable Human Memory T Cells Quantifiable by Cultured Enzyme-Linked Immunospot Assays Are Induced by Heterologous Prime Boost Immunization and Correlate with Protection against Malaria. <i>Journal of Immunology</i> , 2005, 175, 5675-5680.	0.4	123
78	Genomic modulators of gene expression in human neutrophils. <i>Nature Communications</i> , 2015, 6, 7545.	5.8	120
79	Evolution, revolution and heresy in the genetics of infectious disease susceptibility. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2012, 367, 840-849.	1.8	117
80	Association between a common immunoglobulin heavy chain allele and rheumatic heart disease risk in Oceania. <i>Nature Communications</i> , 2017, 8, 14946.	5.8	114
81	Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against <i>Plasmodium falciparum</i> infection in Kenyan adults. <i>Science Translational Medicine</i> , 2015, 7, 286re5.	5.8	113
82	CD8+ T Effector Memory Cells Protect against Liver-Stage Malaria. <i>Journal of Immunology</i> , 2011, 187, 1347-1357.	0.4	110
83	Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naïve Individuals. <i>Journal of Infectious Diseases</i> , 2015, 211, 1076-1086.	1.9	110
84	Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in <i>Mycobacterium tuberculosis</i> -infected Individuals. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 724-733.	2.5	107
85	A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years. <i>PLoS ONE</i> , 2012, 7, e48322.	1.1	107
86	Coadministration of Seasonal Influenza Vaccine and MVA-NP+M1 Simultaneously Achieves Potent Humoral and Cell-Mediated Responses. <i>Molecular Therapy</i> , 2014, 22, 233-238.	3.7	101
87	Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial. <i>PLoS ONE</i> , 2008, 3, e1493.	1.1	99
88	Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever. <i>Scientific Reports</i> , 2016, 6, 20617.	1.6	98
89	Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming. <i>Nature Medicine</i> , 1999, 5, 565-571.	15.2	96
90	Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01 <sub>B</sub> With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. <i>Journal of Infectious Diseases</i> , 2016, 214, 772-781.	1.9	96

#	ARTICLE	IF	CITATIONS
91	QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION FOR MALARIA DIAGNOSIS AND ITS USE IN MALARIA VACCINE CLINICAL TRIALS. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005, 73, 191-198.	0.6	96
92	Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against <i>Plasmodium berghei</i> . <i>European Journal of Immunology</i> , 2008, 38, 732-741.	1.6	95
93	Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to <i>Plasmodium falciparum</i> using sporozoites administered by intramuscular injection. <i>Frontiers in Microbiology</i> , 2014, 5, 686.	1.5	95
94	High frequencies of circulating IFN- $\gamma$ -secreting CD8 cytotoxic T cells specific for a novel MHC class I-restricted <i>Mycobacterium tuberculosis</i> epitope in <i>M. tuberculosis</i> -infected subjects without disease. <i>European Journal of Immunology</i> , 2000, 30, 2713-2721.	1.6	94
95	Language continuity despite population replacement in Remote Oceania. <i>Nature Ecology and Evolution</i> , 2018, 2, 731-740.	3.4	91
96	Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. <i>European Journal of Immunology</i> , 1996, 26, 1951-1959.	1.6	89
97	Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced Immunodominance. <i>Journal of Immunology</i> , 2005, 175, 7264-7273.	0.4	89
98	The Induction and Persistence of T Cell IFN- $\gamma$ Responses after Vaccination or Natural Exposure Is Suppressed by <i>Plasmodium falciparum</i> . <i>Journal of Immunology</i> , 2007, 179, 4193-4201.	0.4	88
99	Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA). <i>PLoS ONE</i> , 2008, 3, e1638.	1.1	87
100	A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. <i>Vaccine</i> , 2006, 24, 2850-2859.	1.7	86
101	Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909. <i>PLoS ONE</i> , 2011, 6, e22271.	1.1	84
102	Genetic susceptibility to invasive Salmonella disease. <i>Nature Reviews Immunology</i> , 2015, 15, 452-463.	10.6	81
103	Protection from <i>Plasmodium berghei</i> infection by priming and boosting T <sub>H</sub> 1 cells to a single class I-restricted epitope with recombinant carriers suitable for human use. <i>European Journal of Immunology</i> , 1998, 28, 4345-4355.	1.6	80
104	Optimising Controlled Human Malaria Infection Studies Using Cryopreserved <i>P. falciparum</i> Parasites Administered by Needle and Syringe. <i>PLoS ONE</i> , 2013, 8, e65960.	1.1	80
105	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T <sub>H</sub> 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	5.8	80
106	Human vaccination against <i>Plasmodium vivax</i> Duffy-binding protein induces strain-transcending antibodies. <i>JCI Insight</i> , 2017, 2, .	2.3	78
107	Enhancing Blood-Stage Malaria Subunit Vaccine Immunogenicity in Rhesus Macaques by Combining Adenovirus, Poxvirus, and Protein-in-Adjuvant Vaccines. <i>Journal of Immunology</i> , 2010, 185, 7583-7595.	0.4	76
108	Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 706-714.	1.4	73

#	ARTICLE	IF	CITATIONS
109	Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. <i>Vaccine</i> , 2005, 23, 857-864.	1.7	72
110	Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005, 73, 191-8.	0.6	71
111	Genetic analysis of host-parasite coevolution in human malaria. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 1997, 352, 1317-1325.	1.8	70
112	Identification of Targets of CD8+ T Cell Responses to Malaria Liver Stages by Genome-wide Epitope Profiling. <i>PLoS Pathogens</i> , 2013, 9, e1003303.	2.1	70
113	Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. <i>Nature Communications</i> , 2018, 9, 2441.	5.8	69
114	Identification of antigens presented by MHC for vaccines against tuberculosis. <i>Npj Vaccines</i> , 2020, 5, 2.	2.9	69
115	Microneedle Array Design Determines the Induction of Protective Memory CD8+ T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice. <i>PLoS ONE</i> , 2011, 6, e22442.	1.1	68
116	Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial. <i>Molecular Therapy</i> , 2014, 22, 2142-2154.	3.7	68
117	Prime and target immunization protects against liver-stage malaria in mice. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	68
118	Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. <i>Vaccine</i> , 2010, 29, 256-265.	1.7	67
119	Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 3020-3032.	1.4	67
120	Dry-Coated Live Viral Vector Vaccines Delivered by Nanopatch Microprojections Retain Long-Term Thermostability and Induce Transgene-Specific T Cell Responses in Mice. <i>PLoS ONE</i> , 2013, 8, e67888.	1.1	66
121	Genetic linkage of mild malaria to the major histocompatibility complex in Gambian children: study of affected sibling pairs. <i>BMJ: British Medical Journal</i> , 1997, 315, 96-97.	2.4	66
122	Comparison of Clinical and Parasitological Data from Controlled Human Malaria Infection Trials. <i>PLoS ONE</i> , 2012, 7, e38434.	1.1	66
123	Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria. <i>Cell Host and Microbe</i> , 2009, 5, 95-105.	5.1	65
124	Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure. <i>PLoS ONE</i> , 2014, 9, e107903.	1.1	65
125	Native American gene flow into Polynesia predating Easter Island settlement. <i>Nature</i> , 2020, 583, 572-577.	13.7	64
126	Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults. <i>PLoS ONE</i> , 2013, 8, e57726.	1.1	64



#	ARTICLE	IF	CITATIONS
127	Association of hepatitis B surface antigen carriage with severe malaria in Gambian children. <i>Nature Medicine</i> , 1995, 1, 374-375.	15.2	62
128	Safety, Immunogenicity, and Efficacy of Prime-Boost Immunization with Recombinant Poxvirus FP9 and Modified Vaccinia Virus Ankara Encoding the Full-Length Plasmodium falciparum Circumsporozoite Protein. <i>Infection and Immunity</i> , 2006, 74, 2706-2716.	1.0	62
129	Consanguinity and susceptibility to infectious diseases in humans. <i>Biology Letters</i> , 2009, 5, 574-576.	1.0	62
130	Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity. <i>Journal of Immunology</i> , 2005, 175, 599-606.	0.4	60
131	A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 290-295.	3.3	59
132	Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal. <i>Journal of Infectious Diseases</i> , 2019, 219, 1187-1197.	1.9	59
133	Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. <i>PLoS ONE</i> , 2007, 2, e707.	1.1	57
134	The Requirement for Potent Adjuvants To Enhance the Immunogenicity and Protective Efficacy of Protein Vaccines Can Be Overcome by Prior Immunization with a Recombinant Adenovirus. <i>Journal of Immunology</i> , 2011, 187, 2602-2616.	0.4	55
135	Cytotoxic T lymphocytes to Plasmodium falciparum epitopes in an area of intense and perennial transmission in Tanzania. <i>European Journal of Immunology</i> , 1996, 26, 773-779.	1.6	54
136	PTPN22 and invasive bacterial disease. <i>Nature Genetics</i> , 2006, 38, 499-500.	9.4	54
137	Activation-induced Markers Detect Vaccine-Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials. <i>Vaccines</i> , 2018, 6, 50.	2.1	54
138	The Immunogenetics of Resistance to Malaria. <i>Proceedings of the Association of American Physicians</i> , 1999, 111, 272-277.	2.1	54
139	Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria Infection. <i>Journal of Infectious Diseases</i> , 2013, 208, 340-345.	1.9	53
140	Efficacy of a Plasmodium vivax Malaria Vaccine Using ChAd63 and Modified Vaccinia Ankara Expressing Thrombospondin-Related Anonymous Protein as Assessed with Transgenic Plasmodium berghei Parasites. <i>Infection and Immunity</i> , 2014, 82, 1277-1286.	1.0	53
141	Progress with viral vectored malaria vaccines: A multi-stage approach involving 'unnatural immunity'. <i>Vaccine</i> , 2015, 33, 7444-7451.	1.7	53
142	First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children. <i>PLoS ONE</i> , 2018, 13, e0208328.	1.1	53
143	Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. <i>Molecular Therapy</i> , 2016, 24, 1470-1477.	3.7	52
144	Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice. <i>Virology Journal</i> , 2013, 10, 349.	1.4	51

#	ARTICLE	IF	CITATIONS
145	Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. <i>Npj Vaccines</i> , 2018, 3, 49.	2.9	51
146	Direct processing and presentation of antigen from malaria sporozoites by professional antigen-presenting cells in the induction of CD8 + T cell responses. <i>Immunology and Cell Biology</i> , 2005, 83, 307-312.	1.0	49
147	Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations. <i>Molecular Therapy</i> , 2014, 22, 1992-2003.	3.7	49
148	Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates. <i>Scientific Reports</i> , 2015, 5, 11820.	1.6	49
149	A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS. <i>PLoS ONE</i> , 2014, 9, e115161.	1.1	48
150	Estimating the burden of iron deficiency among African children. <i>BMC Medicine</i> , 2020, 18, 31.	2.3	47
151	A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. <i>Vaccine</i> , 2011, 29, 7514-7522.	1.7	46
152	Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route. <i>Scientific Reports</i> , 2014, 4, 6154.	1.6	46
153	Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against <i>Plasmodium falciparum</i> Infection in Adults in Senegal. <i>PLoS ONE</i> , 2016, 11, e0167951.	1.1	46
154	Human genetic and metabolite variation reveals that methylthioadenosine is a prognostic biomarker and an inflammatory regulator in sepsis. <i>Science Advances</i> , 2017, 3, e1602096.	4.7	46
155	Transgene Optimization, Immunogenicity and In Vitro Efficacy of Viral Vectored Vaccines Expressing Two Alleles of <i>Plasmodium falciparum</i> AMA1. <i>PLoS ONE</i> , 2011, 6, e20977.	1.1	45
156	Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa. <i>PLoS ONE</i> , 2008, 3, e2921.	1.1	45
157	Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood. <i>European Journal of Immunology</i> , 1995, 25, 1783-1787.	1.6	44
158	Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors. <i>Biotechnology and Bioengineering</i> , 2012, 109, 719-728.	1.7	44
159	Combination of Protein and Viral Vaccines Induces Potent Cellular and Humoral Immune Responses and Enhanced Protection from Murine Malaria Challenge. <i>Infection and Immunity</i> , 2007, 75, 5819-5826.	1.0	43
160	Fusion of the <i>Mycobacterium tuberculosis</i> Antigen 85A to an Oligomerization Domain Enhances Its Immunogenicity in Both Mice and Non-Human Primates. <i>PLoS ONE</i> , 2012, 7, e33555.	1.1	43
161	Analysis of human B cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection. <i>Immunology</i> , 2014, 141, 628-644.	2.0	43
162	Chronic hepatitis C viral infection subverts vaccine-induced T cell immunity in humans. <i>Hepatology</i> , 2016, 63, 1455-1470.	3.6	43

#	ARTICLE	IF	CITATIONS
163	TMEM203 is a binding partner and regulator of STING-mediated inflammatory signaling in macrophages. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 16479-16488.	3.3	43
164	Combining Liver- and Blood-Stage Malaria Viral-Vectored Vaccines: Investigating Mechanisms of CD8+ T Cell Interference. <i>Journal of Immunology</i> , 2011, 187, 3738-3750.	0.4	41
165	Rational development of a protective <i>P. vivax</i> vaccine evaluated with transgenic rodent parasite challenge models. <i>Scientific Reports</i> , 2017, 7, 46482.	1.6	41
166	Cryopreservation-related loss of antigen-specific IFN $\gamma$ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy. <i>Vaccine</i> , 2017, 35, 1898-1906.	1.7	40
167	A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006870.	1.3	40
168	Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies. <i>Malaria Journal</i> , 2015, 14, 33.	0.8	39
169	Polymorphism in a lincRNA Associates with a Doubled Risk of Pneumococcal Bacteremia in Kenyan Children. <i>American Journal of Human Genetics</i> , 2016, 98, 1092-1100.	2.6	39
170	Tailoring a <i>Plasmodium vivax</i> Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors. <i>Infection and Immunity</i> , 2018, 86, .	1.0	39
171	Defence by diversity. <i>Nature</i> , 1999, 398, 668-669.	13.7	38
172	RNA and Imidazoquinolines Are Sensed by Distinct TLR7/8 Ectodomain Sites Resulting in Functionally Disparate Signaling Events. <i>Journal of Immunology</i> , 2014, 192, 5963-5973.	0.4	38
173	Searching for the human genetic factors standing in the way of universally effective vaccines. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2015, 370, 20140341.	1.8	38
174	Iron Status and Associated Malaria Risk Among African Children. <i>Clinical Infectious Diseases</i> , 2019, 68, 1807-1814.	2.9	38
175	Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity. <i>Molecular Therapy</i> , 2012, 20, 1633-1647.	3.7	37
176	The utility of <i>Plasmodium berghei</i> as a rodent model for anti-merozoite malaria vaccine assessment. <i>Scientific Reports</i> , 2013, 3, 1706.	1.6	36
177	Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice. <i>Scientific Reports</i> , 2015, 5, 16756.	1.6	36
178	Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. <i>Vaccines</i> , 2016, 4, 27.	2.1	35
179	Malaria is a cause of iron deficiency in African children. <i>Nature Medicine</i> , 2021, 27, 653-658.	15.2	35
180	HIV and HLA: Confusion or complexity?. <i>Nature Medicine</i> , 1996, 2, 395-396.	15.2	34

#	ARTICLE	IF	CITATIONS
181	Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants. <i>Molecular Therapy</i> , 2017, 25, 547-559.	3.7	34
182	Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. <i>Scientific Reports</i> , 2018, 8, 3390.	1.6	34
183	Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 16, 108-125.	1.8	34
184	EX VIVO INTERFERON-GAMMA IMMUNE RESPONSE TO THROMBOSPONDIN-RELATED ADHESIVE PROTEIN IN COASTAL KENYANS: LONGEVITY AND RISK OF PLASMODIUM FALCIPARUM INFECTION. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003, 68, 421-430.	0.6	34
185	Enhanced Vaccine-Induced CD8+ T Cell Responses to Malaria Antigen ME-TRAP by Fusion to MHC Class II Invariant Chain. <i>PLoS ONE</i> , 2014, 9, e100538.	1.1	33
186	Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats. <i>Npj Vaccines</i> , 2019, 4, 44.	2.9	31
187	Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	31
188	A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. <i>Nature Communications</i> , 2021, 12, 4636.	5.8	31
189	Paths and timings of the peopling of Polynesia inferred from genomic networks. <i>Nature</i> , 2021, 597, 522-526.	13.7	31
190	Induction of CD8+ T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine. <i>Vaccine</i> , 2015, 33, 3248-3255.	1.7	30
191	Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with <i>Plasmodium falciparum</i> Circumsporozoite Protein Antigens. <i>Journal of Immunology</i> , 2018, 201, 1315-1326.	0.4	30
192	Recombinant Viral-Vectored Vaccines Expressing <i>Plasmodium chabaudi</i> Apical Membrane Antigen 1: Mechanisms of Vaccine-Induced Blood-Stage Protection. <i>Journal of Immunology</i> , 2012, 188, 5041-5053.	0.4	29
193	Risk of nontyphoidal <i>Salmonella</i> bacteraemia in African children is modified by STAT4. <i>Nature Communications</i> , 2018, 9, 1014.	5.8	29
194	Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle. <i>Vaccine</i> , 2016, 34, 2296-2298.	1.7	28
195	External Quality Assurance of Malaria Nucleic Acid Testing for Clinical Trials and Eradication Surveillance. <i>PLoS ONE</i> , 2014, 9, e97398.	1.1	28
196	Identification of host-pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank. <i>Nature Communications</i> , 2022, 13, 1818.	5.8	28
197	A loss-of-function <i>IFNAR1</i> allele in Polynesia underlies severe viral diseases in homozygotes. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	28
198	Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M. <i>Vaccine</i> , 2017, 35, 6208-6217.	1.7	27

#	ARTICLE	IF	CITATIONS
199	A <i>P. falciparum</i> NF54 Reporter Line Expressing mCherry-Luciferase in Gametocytes, Sporozoites, and Liver-Stages. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 96.	1.8	27
200	Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial. , 2020, 8, e000928.		27
201	CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria. <i>Frontiers in Immunology</i> , 2018, 9, 1660.	2.2	26
202	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. <i>JCI Insight</i> , 2022, 7, .	2.3	26
203	Vaccines and global health. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2011, 366, 2733-2742.	1.8	25
204	Prevalence of HBV core promoter/precore/core mutations in Gambian chronic carriers. <i>Journal of Medical Virology</i> , 2001, 65, 664-670.	2.5	24
205	Variants in the Mannose-binding Lectin Gene <i>MBL2</i> do not Associate With Sepsis Susceptibility or Survival in a Large European Cohort. <i>Clinical Infectious Diseases</i> , 2015, 61, 695-703.	2.9	24
206	Improved method for distinguishing the human source of mosquito blood meals between close family members. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2000, 94, 572-574.	0.7	23
207	An integrated expression phenotype mapping approach defines common variants in <i>LEP</i> , <i>ALOX15</i> and <i>CAPNS1</i> associated with induction of IL-6. <i>Human Molecular Genetics</i> , 2010, 19, 720-730.	1.4	23
208	T Cell Responses Induced by Adenoviral Vectored Vaccines Can Be Adjuvanted by Fusion of Antigen to the Oligomerization Domain of C4b-Binding Protein. <i>PLoS ONE</i> , 2012, 7, e44943.	1.1	23
209	Assessment of Immune Interference, Antagonism, and Diversion following Human Immunization with Biallelic Blood-Stage Malaria Viral-Vectored Vaccines and Controlled Malaria Infection. <i>Journal of Immunology</i> , 2013, 190, 1135-1147.	0.4	23
210	Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial. <i>Frontiers in Immunology</i> , 2017, 8, 1551.	2.2	23
211	Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line. <i>Vaccines</i> , 2019, 7, 33.	2.1	23
212	Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection. <i>PLoS ONE</i> , 2012, 7, e50447.	1.1	23
213	Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of <i>Plasmodium falciparum</i> infection. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003, 68, 421-30.	0.6	23
214	Induction of CD8 + T $\alpha$ lymphocyte responses to a secreted antigen of <i>Mycobacterium tuberculosis</i> by an attenuated vaccinia virus. <i>Immunology and Cell Biology</i> , 2001, 79, 569-575.	1.0	21
215	Malaria vaccines: identifying <i>Plasmodium falciparum</i> liver-stage targets. <i>Frontiers in Microbiology</i> , 2015, 6, 965.	1.5	21
216	Profiling the host response to malaria vaccination and malaria challenge. <i>Vaccine</i> , 2015, 33, 5316-5320.	1.7	21

#	ARTICLE	IF	CITATIONS
217	The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species. <i>Vaccine</i> , 2015, 33, 1121-1128.	1.7	20
218	Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine. <i>Vaccine Journal</i> , 2017, 24, .	3.2	20
219	The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremia. <i>Science Advances</i> , 2019, 5, eaaw0109.	4.7	20
220	Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines. <i>Vaccine</i> , 2009, 27, 5589-5598.	1.7	19
221	Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vected Vaccine. <i>Vaccines</i> , 2019, 7, 40.	2.1	19
222	Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8+ T Cell Responses. <i>Scientific Reports</i> , 2018, 8, 15020.	1.6	18
223	Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii. <i>PLoS ONE</i> , 2019, 14, e0210407.	1.1	18
224	The Threshold of Protection from Liver-Stage Malaria Relies on a Fine Balance between the Number of Infected Hepatocytes and Effector CD8+ T Cells Present in the Liver. <i>Journal of Immunology</i> , 2017, 198, 2006-2016.	0.4	17
225	Development of an In Vitro Assay and Demonstration of Plasmodium berghei Liver-Stage Inhibition by TRAP-Specific CD8+ T Cells. <i>PLoS ONE</i> , 2015, 10, e0119880.	1.1	17
226	Maintenance of MHC polymorphism. <i>Nature</i> , 1992, 355, 403-403.	13.7	15
227	A distinctive peptide binding motif for HLA-DRB1 * 0407, an HLA-DR4 subtype not associated with rheumatoid arthritis. <i>Immunogenetics</i> , 1997, 45, 229-232.	1.2	15
228	Workshop report: Malaria vaccine development in Europe“preparing for the future. <i>Vaccine</i> , 2015, 33, 6137-6144.	1.7	15
229	An in vitro assay to measure antibody-mediated inhibition of P. berghei sporozoite invasion against P. falciparum antigens. <i>Scientific Reports</i> , 2017, 7, 17011.	1.6	15
230	Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model. <i>Scientific Reports</i> , 2018, 8, 3896.	1.6	15
231	Vaccine innovations for emerging infectious diseases“a symposium report. <i>Annals of the New York Academy of Sciences</i> , 2020, 1462, 14-26.	1.8	15
232	Generation of Novel Plasmodium falciparum NF135 and NF54 Lines Expressing Fluorescent Reporter Proteins Under the Control of Strong and Constitutive Promoters. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 270.	1.8	14
233	A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice. <i>Molecular Therapy</i> , 2022, 30, 2024-2047.	3.7	14
234	Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter. <i>Vaccine</i> , 2016, 34, 49-55.	1.7	13

#	ARTICLE	IF	CITATIONS
235	Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria. <i>Scientific Reports</i> , 2017, 7, 7284.	1.6	13
236	Immunological considerations for SARS-CoV-2 human challenge studies. <i>Nature Reviews Immunology</i> , 2020, 20, 715-716.	10.6	13
237	Ancient DNA reveals five streams of migration into Micronesia and matrilocality in early Pacific seafarers. <i>Science</i> , 2022, 377, 72-79.	6.0	13
238	Assessment of Chimpanzee Adenovirus Serotype 63 Neutralizing Antibodies Prior to Evaluation of a Candidate Malaria Vaccine Regimen Based on Viral Vectors. <i>Vaccine Journal</i> , 2014, 21, 901-903.	3.2	12
239	Genetic variation in VAC14 is associated with bacteremia secondary to diverse pathogens in African children. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3601-E3603.	3.3	12
240	Distinguishing malaria and influenza: Early clinical features in controlled human experimental infection studies. <i>Travel Medicine and Infectious Disease</i> , 2012, 10, 192-196.	1.5	10
241	Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice. <i>Scientific Reports</i> , 2021, 11, 10792.	1.6	10
242	Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy. , 2021, 9, e003218.		10
243	Identification of 34 Novel Proinflammatory Proteins in a Genome-Wide Macrophage Functional Screen. <i>PLoS ONE</i> , 2012, 7, e42388.	1.1	9
244	The Human Leukocyte Antigen Locus and Rheumatic Heart Disease Susceptibility in South Asians and Europeans. <i>Scientific Reports</i> , 2020, 10, 9004.	1.6	9
245	Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule. <i>Scientific Reports</i> , 2020, 10, 5716.	1.6	9
246	Rare Variants in MYD88, IRAK4 and IKBKG and Susceptibility to Invasive Pneumococcal Disease: A Population-Based Case-Control Study. <i>PLoS ONE</i> , 2015, 10, e0123532.	1.1	8
247	4-1BBL Enhances CD8+ T Cell Responses Induced by Vectored Vaccines in Mice but Fails to Improve Immunogenicity in Rhesus Macaques. <i>PLoS ONE</i> , 2014, 9, e105520.	1.1	7
248	Towards a multi-antigen multi-stage malaria vaccine. <i>Malaria Journal</i> , 2014, 13, .	0.8	7
249	DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines. <i>Diseases (Basel, Switzerland)</i> , 2018, 6, 107.	1.0	7
250	Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria. <i>Infection and Immunity</i> , 2020, 88, .	1.0	7
251	Low immunogenicity of malaria pre-erythrocytic stages can be overcome by vaccination. <i>EMBO Molecular Medicine</i> , 2021, 13, e13390.	3.3	7
252	Imputation Performance in Latin American Populations: Improving Rare Variants Representation With the Inclusion of Native American Genomes. <i>Frontiers in Genetics</i> , 2021, 12, 719791.	1.1	7

#	ARTICLE	IF	CITATIONS
253	Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans. <i>Frontiers in Immunology</i> , 2021, 12, 732667.	2.2	6
254	Protection from Plasmodium berghei infection by priming and boosting T <sub>H</sub> 1 cells to a single class II-restricted epitope with recombinant carriers suitable for human use. <i>European Journal of Immunology</i> , 1998, 28, 4345-4355.	1.6	6
255	Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria. <i>Frontiers in Immunology</i> , 2022, 13, 795463.	2.2	6
256	CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination. <i>JCI Insight</i> , 2022, 7, .	2.3	6
257	T-cell receptor variable alpha (TCRAV) polymorphisms in European, Chinese, South American, AfroCaribbean, and Gambian populations. <i>Immunogenetics</i> , 1997, 47, 124-130.	1.2	5
258	Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PflUIS3, PflSA1 and PflSAP2 in Multiple Strains of Mice. <i>PLoS ONE</i> , 2015, 10, e0144515.	1.1	5
259	Modeling Combinations of Pre-erythrocytic Plasmodium falciparum Malaria Vaccines. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 1254-1259.	0.6	5
260	Elevated risk of invasive group A streptococcal disease and host genetic variation in the human leucocyte antigen locus. <i>Genes and Immunity</i> , 2020, 21, 63-70.	2.2	5
261	Risk of pneumococcal bacteremia in Kenyan children with glucose-6-phosphate dehydrogenase deficiency. <i>BMC Medicine</i> , 2020, 18, 148.	2.3	4
262	Quantitative Association Tests of Immune Responses to Antigens of Mycobacterium Tuberculosis: A Study of Twins in West Africa. <i>Twin Research and Human Genetics</i> , 2004, 7, 578-588.	1.3	3
263	Safety and Immunogenicity of Adenovirus and Poxvirus Vected Vaccines against a Mycobacterium Avium Complex Subspecies. <i>Vaccines</i> , 2021, 9, 262.	2.1	3
264	Dissection-independent production of Plasmodium sporozoites from whole mosquitoes. <i>Life Science Alliance</i> , 2021, 4, e202101094.	1.3	2
265	Screening of viral-vectored P. falciparum pre-erythrocytic candidate vaccine antigens using chimeric rodent parasites. <i>PLoS ONE</i> , 2021, 16, e0254498.	1.1	2
266	Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation. <i>Scientific Reports</i> , 2021, 11, 20877.	1.6	2
267	Genetic susceptibility to multifactorial diseases. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1997, 91, 369-371.	0.7	1
268	COVID-19 vaccines for rapid global impact. <i>BJU International</i> , 2021, 127, 137-139.	1.3	1
269	Human genetic susceptibility to infectious disease. , 0, .		1
270	Production of a high purity, C <sub>60</sub> -tagged Hepatitis B surface Antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions. <i>Biotechnology and Bioengineering</i> , 0, , .	1.7	1



#	ARTICLE	IF	CITATIONS
271	Clinical Evaluation of New Immunisation Strategies for Enhancing T Cell Responses against <i>M. Tuberculosis</i> . <i>Clinical Science</i> , 2003, 104, 51P-51P.	0.0	0
272	Identification of Susceptibility Genes for Tuberculosis in Southern and West Africans Using Family-Based Linkage Analysis and Linkage Disequilibrium Mapping. <i>Clinical Science</i> , 2003, 104, 56P-56P.	0.0	0
273	Jenner reborn: a new vaccine institute. <i>Lancet</i> , The, 2009, 373, 445-446.	6.3	0
274	Virus-like particle vaccines. , 2022, , 163-176.		0
275	New Malaria Vaccines: The DNA-MVA Prime-Boost Strategy. , 0, , 87-96.		0